Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

CDKN2B

6 articles · Resources: NCBI Gene, OncoKB

Clinical · Molecular biology · Bioinfo & AI

Pleomorphic Liposarcoma: Comprehensive Genomic Analysis of 39 Cases With Comparison to Other Genomically Complex Sarcomas

Yakoub MA, Saoud C, Kim D, et al.

Genes, chromosomes & cancer

This study conducted comprehensive genomic profiling on 39 cases of pleomorphic liposarcoma (PLPS) to characterize its molecular landscape and compare it with other complex sarcomas like UPS and MFS. Analyses revealed that TP53 (87%) and RB1 (51%) alterations are the most frequent in PLPS, and significantly more common than in UPS and MFS. MYC amplification was associated with significantly shorter overall survival, suggesting a prognostic role. Furthermore, correlations were established between gene alterations and morphological features, including CYSLTR2 alterations in cases with predominant pleomorphic lipoblasts. These findings highlight the molecular distinctiveness of PLPS and provide insights for future diagnostic and therapeutic strategies.

Clinical · Molecular biology · Bioinfo & AI

[Dynamically monitoring circulating tumor DNA as a biomarker for immunotherapy in advanced esophageal squamous cell carcinoma]

Wang BY, Wang HK, Li J, et al.

Zhonghua zhong liu za zhi [Chinese journal of oncology]

This study investigated the clinical value of dynamic monitoring of circulating tumor DNA (ctDNA) in 94 patients with advanced esophageal squamous cell carcinoma (ESCC) receiving sintilimab. The findings indicate that the ctDNA-based molecular tumor burden index (mTBI) serves as a sensitive, real-time biomarker for evaluating immunotherapy efficacy. Patients achieving ctDNA clearance or having a low mTBI after two treatment cycles demonstrated significantly delayed tumor progression and improved overall survival. Dynamic mTBI monitoring showed high consistency with concurrent imaging assessments, suggesting its utility for personalized treatment management.

Clinical · Molecular biology · Bioinfo & AI

Segmental Copy Number Variant Detection Using an Amplicon-Based Next-Generation Sequencing Panel for Integrated Glioma Classification

Sarvananthan K, Santos S, Saylor B, et al.

The Journal of molecular diagnostics

This study describes a custom analysis method for detecting segmental copy number variants (CNVs) using an amplicon-based NGS panel (Oncomine Comprehensive Assay v3) for integrated glioma classification. The developed algorithm identifies critical biomarkers such as 1p/19q codeletion, +7/-10, EGFR amplification, and CDKN2A/B homozygous deletion. Validated across three cohorts, the approach demonstrated 100% concordance with FISH for all biomarkers in the validation cohort. Its clinical implementation significantly reduced required FISH studies by 90%, thereby shortening turnaround times and decreasing molecular testing costs.

Clinical · Molecular biology

Clinicogenomic analysis of EGFR-mutant lung tumors identifies Rb pathway inactivation as a hallmark of squamous transformation

Dymun A, Jeng MY, Elkrief A, et al.

Science translational medicine

This study investigates histologic transformation to lung squamous cell carcinoma (LUSC) in EGFR-mutant lung adenocarcinoma (LUAD) patients, an underrecognized resistance mechanism. Multiomic analyses revealed that patients with transforming or adenosquamous (LUAS) phenotypes experienced shorter overall survival on first-line osimertinib. Inactivation of the retinoblastoma (Rb) pathway, particularly via CDKN2A/B deletions, was identified as a key driver of this transformation. Furthermore, MET pathway upregulation was observed, and combined EGFR and MET inhibition demonstrated efficacy in preclinical models. These findings suggest novel strategies to counteract this aggressive form of resistance.

Clinical · Molecular biology

ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line Osimertinib

Piotrowska Z, Ahn MJ, Voon PJ, et al.

Cancer discovery

The prospective, multicenter ELIOS study characterized acquired resistance mechanisms to first-line osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). By analyzing paired tumor biopsies taken pre-treatment and post-progression, the study identified frequent alterations including MET amplification, CDKN2A/CDKN2B and MTAP deletions, and the EGFR C797S mutation. Proteogenomic analysis also revealed high TROP2 expression, irrespective of genetic alterations. The findings highlight the heterogeneous nature of resistance and the complementary utility of tissue and liquid biopsies for alteration detection. This study emphasizes the need for therapeutic strategies targeting multiple resistance pathways.

Clinical · Molecular biology

Genetic mutations in metastatic adenocarcinoma of unknown primary

Nagano H, Kiyama S, Kyutoku T, et al.

Otolaryngologia polska = The Polish otolaryngology

This study analyzed the genomic profile of 480 patients with metastatic adenocarcinoma of unknown primary (ACUP) using the FoundationOne CDx platform. The most frequent mutations included TP53, KRAS, and CDKN2A. Results showed that GNAS and PIK3CA mutations were associated with better overall survival. Conversely, ARID1A and NOTCH1 alterations were linked to a worse prognosis. These findings highlight the significance of specific genomic alterations as prognostic markers in ACUP.